QIAGEN NV

ISIN: NL0015001WM6 WKN: N72482149 Asset Class: Stock



Company Profile

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. The firm assay technologies make these biomolecules visible and ready for analysis. Its bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996, and is headquartered in Venlo, the Netherlands.

Financial figures, Fiscal year: from 01.01. to 31.12.

	20	2023		2022		2021	
Financial figures		Liabilities and equity		Liabilities and equity		Liabilities and equity	
Current assets	2,147,560,000		2,393,952,000		2,109,602,000		
Common stock capital		2,702,000		2,702,000		2,702,000	
Fixed assets	3,967,630,000		3,893,783,000		4,037,352,000		
Equity capital of a company		3,807,764,000		3,466,611,000		3,096,550,000	
Cash and cash equivalents	668,084,000		730,669,000		880,516,000		
Accrued liabilities		12,100,000		11,900,000		0	
Other assets	-		-		-		
Current liabilities		1,079,293,000		974,523,000		1,517,470,000	
Prepayments and accrued income	-		-		-		
Non-current liabilities		1,228,133,000		1,846,601,000		1,532,934,000	
Different income		-		-		-	
Other liabilities		202,346,000		273,897,000		324,665,000	
Total assets	6,115,190,000	6,115,190,000	6,287,735,000	6,287,735,000	6,146,954,000	6,146,954,000	

Balance notes

	2023	2022	2021
Accounting standard	US-GAAP	US-GAAP	US-GAAP
Employees	5,967	6,178	6,028
Equity ratio	62.27%	55.13%	50.38%
Debt-equity ratio	60.60%	81.38%	98.51%

Others

	2023	2022	2021
Tax Expense Rate	20.59%	17.44%	18.09%

QIAGEN NV

ISIN: NL0015001WM6 WKN: N72482149 Asset Class: Stock

Income statement			
	2023	2022	2021
Turnover	1,965,311,000	2,141,518,000	2,251,657,000
Net income	341,303,000	423,211,000	512,599,000
EBIT	373,222,789	496,920,983	619,308,092
Operating income before taxes	429,809,000	512,601,000	625,833,000
Cash Flow	459,455,000	715,264,000	639,001,000
Net interest income	25,582,000	-25,600,000	-44,922,000
Research and development expenses	198,511,000	189,859,000	189,964,000
Income taxes	88,506,000	89,390,000	113,234,000
Result from investments in subsidaries, associates and other	-	-	-
Revenues per employee	304,101	320,049	344,883

Board of Directors	
Lawrence Rosen	Chairman of Supervisory Board
Elaine Mardis	Member of Supervisory Board
Eva Pisa	Member of Supervisory Board
Metin Colpan	Member of Supervisory Board
Ross Levine	Member of Supervisory Board
Toralf Haag	Member of Supervisory Board
Bert van Meurs	Member of Supervisory Board
Elizabeth Tallett	Member of Supervisory Board
Eva van Pelt	Member of Supervisory Board
Stephen Rusckowski	Member of Supervisory Board

Members of Management Board		
Chairman of Managing Board		
Member of Executive Committee		